Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcuma xanthorriza, commonly known as Temulawak or Javanese turmeric, is a botanical extract native to Indonesia. In dermatological research, a 10% cream formulation of the extract is being evaluated as a depigmentation agent for the treatment of epidermal-type melasma. Its therapeutic effect is mediated through the inhibition of the tyrosinase enzyme, which is essential for melanin synthesis, as well as the reduction of Microphthalmia-associated transcription factor (MITF) transcription and the inhibition of alpha-melanocyte-stimulating hormone (α-MSH). These actions collectively reduce melanin production and improve skin brightness, offering a potential alternative to traditional treatments like hydroquinone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcuma xanthorriza.